Loading...
•
Dec 31, 2020
iTeos Therapeutics Q4 2020 Earnings Report
Reported financial results for the fourth quarter and full year ended December 31, 2020 and provided recent business highlights.
Key Takeaways
iTeos Therapeutics reported its Q4 and full year 2020 financial results, highlighting a strong cash position of $336.3 million and progress in advancing its Phase 1/2a trials for inupadenant and EOS-448.
Cash and cash equivalents totaled $336.3 million as of December 31, 2020.
R&D expenses were $9.2 million for the quarter.
G&A expenses were $5.7 million for the quarter.
Net loss attributable to common shareholders was $14.9 million, or a net loss of $0.43 per basic and diluted share, for the quarter.
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...